Dr. Novack was cited in an article in the New York Times on 4 April 2024 regarding the safety of ophthalmic medications. He noted that eye-care products have a higher risk of health harm because they’re applied directly to the eye. Also, that manufacturing and storing these products has to maintain sterility and stability.
Dr. Gary Novack is a board-certified clinical pharmacologist and President of PharmaLogic Development with more than 40 years of experience in ophthalmic drug development, clinical research, and FDA regulatory strategy.
He has consulted for over 100 pharmaceutical and medical device companies and authored more than 400 scientific publications.